Mebias Discovery Inc

MEB-1170: A New Chemical Entity for the Treatment of Opioid Use Disorder - Project Summary / Abstract Mebias Discovery, Inc. Is Developing a New Chemical Entity, MEB-1170, to Treat Opioid Use Disorder (OUD) as a Maintenance Medication. Currently, All of the Fda-approved Medications for Treating Oud (MOUD) – Buprenorphine, Methadone, and Naltrexone – Come With Liabilities (abuse Potential, Medication Diversion, Need for Detoxification Prior to Administration, Risk of Respiratory Depression, Etc.) and ~50% of Patients Discontinue Treatment After 6 MONTHS.1,2 MEB-1170 Is a Full Mu Opioid Receptor Agonist and Partial Kappa Opioid Receptor Agonist That Has a Unique Pharmacological Profile. Specifically, It Produces a Robust Analgesic Response That Is Mediated Through Mu Opioid Receptors But Has No Abuse Liability as Measured in Multiple Preclinical Assays (conditioned Place Preference, Intravenous Drug Self-administration, Drug Discrimination) and No Typical Opioid-related Adverse Effects Such as Respiratory Depression, Constipation, and Sedation. a Phase 1 Single Ascending Dose Study Supported Its Safety and Tolerability in Healthy Adult Volunteers. in the UG3 Phase of the Proposed Research, We Will Complete Preclinical Studies in Rodents and Non-human Primates to Evaluate the Efficacy of MEB-1170 as an Moud. We Will Assess the Ability of MEB-1170 to Reduce Fentanyl Self- Administration, as Well as Its Propensity to Produce Respiratory Depression and Precipitate Opioid Withdrawal in Opioid- Dependent Animals. in the UH3 Phase, We Will Conduct a Phase 1 Multiple Ascending Dose Clinical Trial to Further Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MEB-1170 in Healthy Adult Volunteers Over a 10-DAY Regimen. in Addition, We Will Conduct a Phase 1B Clinical Study to Assess the Ability of MEB-1170 to Reduce Fentanyl-induced Ratings of Drug Liking and Precipitate Opioid Withdrawal in Opioid-dependent Individuals With Oud Who Are Not Currently Not Seeking Treatment for Oud. Our Overarching Goal Is to Develop MEB-1170 as a Safe and Effective Moud to Prevent Relapse and Facilitate Long-term Recovery. 1 Montoya, I. D. & Volkow, N. D. Iuphar Review: New Strategies for Medications to Treat Substance Use Disorders. Pharmacol Res 200, 107078, DOI:10.1016/J.PHRS.2024.107078 (2024). 2 Marsden, J. Et Al. Measurement-based Care Using DSM-5 for Opioid Use Disorder: Can We Make Opioid Medication Treatment More Effective? Addiction 114, 1346-1353, DOI:10.1111/ADD.14546 (2019).